Clinical Trial Update: [18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001) [Phase 1]

View source ↗

Summary

First-in-human validation study of the PET tracer [18F]MK-6240 (MK-6240-001) completed in Phase 1 for Alzheimer's disease and amnestic mild cognitive impairment…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Amnestic Mild Cognitive Impairment

Drugs mentioned

• [18F]MK-6240 (MK-6240)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Alzheimer's Disease, Amnestic Mild Cognitive Impairment | Phase 1 | Status: COMPLETED | Results posted: 2018-07-23